Pfizer (PFE) Long-Term Deferred Tax (2009 - 2026)

Pfizer (PFE) has 18 years of Long-Term Deferred Tax data on file, last reported at $10.0 billion in Q1 2026.

• Quarterly Long-Term Deferred Tax rose 4.43% year-over-year to $10.0 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.0 billion (up 4.43% YoY) and the FY2025 annual result came in at $9.7 billion, up 11.97% from the prior year.
• Long-Term Deferred Tax rose to $10.0 billion in Q1 2026 per PFE's latest filing, from $9.7 billion in the prior quarter.
• Across five years, Long-Term Deferred Tax topped out at $11.0 billion in Q3 2025 and bottomed at $3.7 billion in Q4 2023.
• The 5-year median for Long-Term Deferred Tax is $7.9 billion (2024), against an average of $7.9 billion.
• The widest annual swing landed in 2022, when Long-Term Deferred Tax surged 159.91%; it then sank 44.63% in 2023.
• Tracing PFE's Long-Term Deferred Tax over 5 years: stood at $6.7 billion in 2022, then slumped by 44.63% to $3.7 billion in 2023, then soared by 133.73% to $8.7 billion in 2024, then grew by 11.97% to $9.7 billion in 2025, then grew by 2.74% to $10.0 billion in 2026.
• Per Business Quant, the three latest PFE Long-Term Deferred Tax figures stand at $10.0 billion (Q1 2026), $9.7 billion (Q4 2025), and $11.0 billion (Q3 2025).

Peer Comparison